Your browser doesn't support javascript.
loading
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot, Thomas; Niogret, Julie; Carnet, Marion; Chevrier, Sandy; Humblin, Etienne; Favier, Laure; Bengrine-Lefevre, Leila; Desmoulins, Isabelle; Arnould, Laurent; Boidot, Romain.
Afiliação
  • Collot T; Department of Oncology, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Niogret J; Department of Oncology, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Carnet M; Molecular Biology Unit, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Chevrier S; Molecular Biology Unit, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Humblin E; Centre de Recherche, University Bourgogne Franche-Comté, F-21078 Dijon, France.
  • Favier L; Department of Oncology, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Bengrine-Lefevre L; Department of Oncology, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Desmoulins I; Department of Oncology, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Arnould L; Pathology Unit, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
  • Boidot R; Molecular Biology Unit, Department of Biology and Pathology of Tumors, Georges-François Leclerc Cancer Center, UNICANCER, F-21079 Dijon, France.
Mol Med Rep ; 23(1)2021 01.
Article em En | MEDLINE | ID: mdl-33236159
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Proteína Supressora de Tumor p53 / Poli(ADP-Ribose) Polimerases / Resistencia a Medicamentos Antineoplásicos / Proteína BRCA1 / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação com Perda de Função Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans Idioma: En Revista: Mol Med Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ftalazinas / Piperazinas / Proteína Supressora de Tumor p53 / Poli(ADP-Ribose) Polimerases / Resistencia a Medicamentos Antineoplásicos / Proteína BRCA1 / Inibidores de Poli(ADP-Ribose) Polimerases / Mutação com Perda de Função Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans Idioma: En Revista: Mol Med Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França